Global Non-invasive Prenatal Testing (NIPT) Market Forecast to 2025

March 2019 | 83 pages | ID: G3B1009A7D8EN
Infoholic Research

Abstracts

Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025

[83 pages report] This market research report includes a detailed segmentation of the global non-invasive prenatal testing market – By Application (Trisomy, Microdeletion Syndrome, and Other NIPT Applications), and By Region (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Non-invasive Prenatal Testing Market Research

Infoholic’s market research report predicts that the global non-invasive prenatal testing market will grow at a CAGR of 17.5% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market. The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.

The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology. Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.

According to Infoholic Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24–25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.

By Application:

• Trisomy
• Microdeletion Syndrome
• Other NIPT Applications

In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.

By Regions:

• North America
• Europe
• APAC
• RoW

The global market is dominated by North America, followed by Europe and Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.

Non-Invasive Prenatal Testing Market Research Competitive Analysis – The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity. 10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018. In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Ag?ncia Nacional de Vigil?ncia Sanit?ria, for sale in the country as an IVD. In late 2018, PerkinElmer’s Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017. In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of the Europe’s specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.

Key vendors:

• Natera Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Illumina Inc.
• F. Hoffmann-La Roche
• Beijing Genomics Institute
• LifeCodexx AG
• Quest Diagnostics
• Yourgene Health Plc
• Myriad Genetics Inc.
• NIPD Genetics
• PerkinElmer Inc.
• Next Biosciences (Pty) Limited

Key competitive facts:

• The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
• The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.

Benefits – The report provides complete details about the adoption rate of non-invasive prenatal tests. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:

• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
• Factors influencing the growth of the non-invasive prenatal testing market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
• Key insights related to major segments of the non-invasive prenatal testing market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Contents

List Of Tables

LIST OF TABLES

TABLE 1 FUNDING SCENARIO
TABLE 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION)
TABLE 3 OTHER PROMINENT VENDORS IN THE NON-INVASIVE PRENATAL TESTING MARKET
TABLE 4 NATERA INC.: OFFERINGS
TABLE 5 NATERA INC.: RECENT DEVELOPMENTS
TABLE 6 ILLUMINA INC.: PRODUCT OFFERINGS
TABLE 7 ILLUMINA INC.: RECENT DEVELOPMENTS
TABLE 8 LABORATORY CORPORATION OF AMERICA HOLDINGS: OFFERINGS
TABLE 9 LABORATORY CORPORATION OF AMERICA HOLDINGS: RECENT DEVELOPMENTS
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 12 BEIJING GENOMICS INSTITUTE: PRODUCT OFFERINGS
TABLE 13 BEIJING GENOMICS INSTITUTE: RECENT DEVELOPMENTS
TABLE 14 QUEST DIAGNOSTICS: SNAPSHOT
TABLE 15 QUEST DIAGNOSTICS: RECENT DEVELOPMENTS
TABLE 16 LIFECODEXX AG: SNAPSHOT
TABLE 17 LIFECODEXX AG: RECENT DEVELOPMENTS
TABLE 18 YOURGENE HEALTH PLC: SNAPSHOT
TABLE 19 YOURGENE HEALTH PLC: RECENT DEVELOPMENTS
TABLE 20 NIPD GENETICS: SNAPSHOT
TABLE 21 NIPD GENETICS: RECENT DEVELOPMENTS
TABLE 22 MYRIAD GENETICS INC.: SNAPSHOT
TABLE 23 MYRIAD GENETICS INC.: RECENT DEVELOPMENTS
TABLE 24 PERKINELMER INC.: SNAPSHOT
TABLE 25 PERKINELMER INC.: RECENT DEVELOPMENTS
TABLE 26 NEXT BIOSCIENCES (PTY) LIMITED: SNAPSHOT
TABLE 27 NEXT BIOSCIENCES (PTY) LIMITED: RECENT DEVELOPMENTS

List Of Figures

LIST OF FIGURES

CHART 1 RESEARCH METHODOLOGY OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
CHART 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE, 2018–2025 ($MILLION)
CHART 3 SEGMENTATION OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
CHART 4 PEST ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
CHART 5 PORTER 5 FORCES ON GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
CHART 6 MARKET DYNAMICS – DRO ANALYSIS
CHART 7 DRO – IMPACT ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET
CHART 8 KEY STAKEHOLDERS
CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2018 (%)
CHART 10 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2025 (%)
CHART 11 TRISOMY MARKET FORECAST, 2018–2025 ($MILLION)
CHART 12 MICRODELETION SYNDROME MARKET FORECAST, 2018–2025 ($MILLION)
CHART 13 OTHER NIPT APPLICATIONS MARKET FORECAST, 2018–2025 ($MILLION)
CHART 14 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2018 (%)
CHART 15 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2025 (%)
CHART 16 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION)
CHART 17 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION)
CHART 18 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION)
CHART 19 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION)
CHART 20 NATERA INC.: OVERVIEW SNAPSHOT
CHART 21 NATERA INC.: GEOGRAPHIC PRESENCE
CHART 22 NATERA INC.: SWOT ANALYSIS
CHART 23 ILLUMINA INC.: OVERVIEW SNAPSHOT
CHART 24 ILLUMINA INC.: BUSINESS UNITS
CHART 25 ILLUMINA INC.: GEOGRAPHIC PRESENCE
CHART 26 ILLUMINA INC.: SWOT ANALYSIS
CHART 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT
CHART 28 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS
CHART 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: GEOGRAPHIC PRESENCE
CHART 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
CHART 31 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
CHART 32 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
CHART 33 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC PRESENCE
CHART 34 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
CHART 35 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS